Elecsys free PSA 08828601160Recalls & reported problems
Roche Diagnostics GmbH · Class 3
All models of Elecsys free PSA (5)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 07613336166673), received between Jul 13, 2022 and Jul 13, 2022 — classified as 1 malfunction.
The most frequently reported specific device problem is “Incorrect Measurement” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Incorrect Measurement1
Patient problems
- No Clinical Signs, Symptoms or Conditions1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
MalfunctionJul 13, 2022Incorrect Measurement; Incorrect Measurement
THE INITIAL REPORTER RECEIVED QUESTIONABLE ELECSYS TOTAL PSA AND ELECSYS FREE PSA IMMUNOASSAY RESULTS FOR ONE PATIENT TESTED ON A COBAS 6000 E 601 MODULE SERIAL NUMBER (B)(4). ON (B)(6) 2022, THE ELECSYS PSA RESULTS WERE NOT REPORTED OUTSIDE THE LABORATORY. THE CUSTOMER PERFORMED REPEAT TESTING WITH THE SAMPLE ON THE SAME E 601 MODULE. ON (B)(6) 2022, A NEW SAMPLE WAS COLLECTED AND TESTED ON THE E 601 MODULE. ON (B)(6) 2022, THE CUSTOMER SENT THE SAMPLE TO A DIFFERENT LABORATORY AND THE SAMPLE WAS TESTED WITH CHEMILUMINESCENCE METHODOLOGY. ON (B)(6) 2022, THE PATIENT'S INITIAL RESULTS ON THE E 601 MODULE WERE TOTAL PSA 0.80 NG/ML AND FREE PSA 1.33 NG/ML. THE PATIENT'S REPEAT RESULTS ON THE E 601 MODULE WERE TOTAL PSA 0.81 NG/ML AND FREE PSA 1.39 NG/ML. ON (B)(6) 2022, THE PATIENT'S NEW SAMPLE WAS TESTED ON THE E 601 MODULE AND THE RESULTS WERE TOTAL PSA 0.084 NG/ML AND FREE PSA 1.30 NG/ML. ON (B)(6) 2022, THE PATIENT'S RESULTS WITH THE CHEMILUMINESCENCE METHODOLOGY WERE TOTAL PSA 0.93 NG/ML AND FREE PSA 0.02 NG/ML. THE ELECSYS TOTAL PSA REAGENT LOT NUMBER WAS 556098 WITH AN EXPIRATION DATE OF 30-NOV-2022. THE ELECSYS FREE PSA REAGENT LOT NUMBER WAS 546160 WITH AN EXPIRATION DATE OF
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 15006114 ↗
Other Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions devices
- Alinity 07P9321Abbott Ireland Diagnostics · Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions1 recall0 reports
- Elecsys free PSA 08828610190Roche Diagnostics GmbH · Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions25 reports
- Dimension Vista® System FPSA Flex® Reagent Cartridge 10445091Siemens Healthcare Diagnostics Inc. · Test,Prostate Specific Antigen,Free,(Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions3 reports
- Elecsys free PSA 07027320190Roche Diagnostics GmbH · Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions2 reports
- Elecsys free PSA 03289788160Roche Diagnostics GmbH · Test,Prostate Specific Antigen,Free,(Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions2 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page